Background Since the advent of the human genome, the era of personalized genomic medicine is indisputably in progress.
Introduction
The purpose of the bioresource program at Baylor is to procure tissue samples of resected liver cancers and gather critical patient and research information that will be used to develop a comprehensive biomedical database. As the fifth most common cancer worldwide, and the third most lethal, hepatocellular carcinoma (HCC) continues to be a global burden [1] . It is an epithelial cancer of hepatocytes [2] and one million cases are diagnosed annually [1] . Identifying genetic patterns unique to cancer types helps to reveal molecular mechanisms enabling novel therapeutic approaches. Efforts at whole exome sequencing are underway for a variety of cancer types, including HCC, where hepatic resection and/or liver transplantation remain the definitive treatment. Many of these HCCs, however, will go on to recur. Examining the role of altered DNA sequences in pathological states could offer mechanisms of progression from cirrhosis to malignancy, risk factors for recurrence, and applicability of current treatment options to a diverse group of people [3] [4] [5] .
The surgeon can be the catalyst for such an ambitious endeavor, as he or she has direct access to patients and their cancerous tissue and can maneuver in both the clinical setting and the basic science arena [6] . This article is intended to serve as a primer for the establishment of a bioresource bank, encapsulating sample acquisition and processing, preservation techniques, pathological considerations, and collection of clinical data elements [7] [8] [9] [10] .
Notably, we address the practicalities and pitfalls we have encountered in our endeavors in an aim for greater consistency and improvement of design.
A bioresource bank
In the new era of personal genomics, physicians and scientists are now responsible for translating molecular and cellular discoveries into practical applications, especially in light of accelerating advances in biomedical technology and analysis [11, 12] . Two decades after the Human Genome Project began, we find ourselves with more powerful and precise DNA sequencing and genotyping methods that are less costly and faster than ever before. The National Cancer Institute (NCI), in concert with the Office of Biorepositories and Biospecimen Research (OBBR) [13] , has commissioned a national, large-scale effort to establish a repository of cancer tissue, titled The Cancer Human Biobank (caHUB) [14] . Having such a repository could lead to high-quality sequences with which to complete the pilot database aptly titled The Cancer Genome Atlas (TCGA). The NCI Best Practices for Biospecimen Resources serves as a guideline for investigators interested in collaboration, and it states that biospecimens of human cancers have become the foundation for developing technology platforms, serving as the critical resource of basic bench science and translational research [15] . The data collected there are driving the course of therapeutic research, as well as the diagnosis of cancer, the identification of preventative measures, and characterization of the disease. Reliability, reproducibility, and quality of the input are of the utmost importance, and standardization of acquisition is an absolute necessity for success [16] . Newer biobanks, such as the one at Baylor, now employ a standard operating procedure directed toward compliance with these standards. Standardization is important to translational cancer research, because quality of output is based on quality of input [17] . Given these factors, biorepositories and the collection process should not be considered a fixed and unchanging activity. Both the biobanks and the means of collection must be flexible to keep up with the advent of new techniques and the emergence of new scientific questions [18] . As participants in a dynamic and nascent science, we are contributing the experience we gain in a comprehensive cancer center toward building a bioresource repository of human hepatocellular carcinoma (HCC) in alignment with NCI/TCGA standards.
Standardized protocols are applied consistently in preparing and storing biospecimens to ensure quality and to avoid introducing variables into research studies. Our protocol was developed in conjunction with NCI Best Practices 2010 to comply with TCGA standards.
Biospecimens are collected from populations with demographic characteristics and diversity appropriate to the scientific goals of research. For our purposes, biospecimens are selected in the light of unanswered questions regarding patients with HCC and its causes.
Prior to implementing a biospecimen bank, it is prudent to assess the resources at hand. Establishing a high-volume biospecimen repository requires resources directed at the following activities [8, 15] :
• Tissue collection, receiving, tracking, and shipping • Immediate and interim processing (i.e., fine and gross dissection benches) • Histological preparation and pathology evaluation • Informatics for validation studies and organization
The undertaking of such a large-scale project, to be fully operational with a sizable tissue bank, requires a multidisciplinary approach. Personnel involved in biospecimen resource management and use, including researchers, technicians, nurses, surgeons, pathologists, anesthesiologists, and assistants, must share the goals of the bioresource repository.
Standard operating procedure (SOP)

Informed consent
Informed consent for tissue collection must be obtained preoperatively from each study participant by the research team. The consent explicitly includes permission for DNA, RNA, and protein extraction, genomic sequencing, release of de-identified clinical information, post-treatment contact, and release of de-identified genomic and clinical information to scientific databases. The risks of participation, including potential loss of confidentiality of genomic information and discomfort associated with blood collection, are to be included. Additionally, relevant Health Insurance Portability and Accountability Act (HIPAA) protections are included in the patient consent.
Specimen de-identification
At the time of enrollment, patients are assigned a unique sequential identification number. This identifier is associated with all tissue samples collected, as well as all data elements acquired while maintaining patient anonymity ( Fig. 1 ).
Tissue collection staff notification
The tissue collection staff is notified at the time of initial surgical incision, and is present in the operating room at completion of resection or completion of explant hepatectomy for transport of the specimen from the operating room to the pathology suite for immediate processing.
Blood collection and storage
For patient comfort, venous or arterial whole blood is collected from participating patients in two 8.5 cc plastic PAXgene blood collection tubes (Qiagen, Valencia, CA) after administration of general anesthesia. The time of collection is recorded. To eliminate potential contamination with non-native leukocytes, patient blood is collected prior to the administration of any blood products or, in the case of transplants, before graft reperfusion.
Blood tubes are labeled using the standard de-identified nomenclature indicating center of origin, sample source, and patient number (Fig. 1) , as well as the time and date of collection. Filled blood tubes are stored at progressively cooler temperatures according to the instructions of the tube manufacturer, for ultimate long-term storage at -80°C.
Liver tissue processing and storage
Our institution employs 2 ml freestanding screwcap cryogenic vials (Phenix Research Products, Candler, NC) for specimen storage. These cryogenic vials are prelabeled to indicate patient, tissue type, and preservation mechanism according to the standardized de-identified nomenclature (Fig. 1) . The time of completion for resection or transplant hepatectomy is then recorded, and the resected liver specimen or recipient explanted liver is immediately transported by tissue collection staff to the Pathology Department for processing.
The pathology technician uses a sterile trimmer blade to serially section the specimen longitudinally into 1 cm slices. The number of grossly identifiable and viable tumors, the locations of these tumors, and the dimensions of each tumor are then recorded. Multiple tumors are numbered sequentially from right lobe to left lobe.
With a new sterile disposable #20 or #22 blade scalpel, a 1 cm 9 1 cm 9 4 cm section of grossly viable tumor is removed. (Care must be taken that a sufficient mass of tumor is available to the pathologist for pathologic diagnosis of the HCC.) In the case of multiple tumors, sections from each tumor are acquired. Tumor tissue is cut into 0.5 cm 9 0.5 cm 9 0.5 cm pieces and divided into three 2 ml cryogenic vials: one containing 1 ml of RNAlater, and two empty cryogenic vials to be flash frozen in liquid nitrogen. Separately, and with a new set of tools, a 1 cm 9 1 cm 9 4 cm section of non-tumor liver tissue at least 2 cm from the tumor margin is removed. For processing of the adjacent non-cancerous tissue, the identical procedure is followed (Fig. 2) . Finally, two 1 cm 9 1 cm 9 0.5 cm segments are removed from each long end of the sectioned tumor and two equivalent segments from the non-tumor liver tissue are placed in a 10 cc container of 10% buffered L10-0248-TF Fig. 1 Labeling and de-identification. L liver, denoting organ; TF tumor frozen, denoting the type of tissue. 10 denotes year; 0248 is the unique identifying number of the patient Fig. 2 Hepatocellular carcinoma tissue processing formalin for subsequent paraffin fixation, slide preparation, and pathologist review.
Our protocol uses RNAlaterÒ (Ambion, Austin, TX ) for immediate RNase activation and RNA isolation per manufacturer's protocol. Tissue preserved in RNAlater will be incubated at 4°C for 24-48 h, after which the supernatant is decanted, and the tissue is stored at -80°C. After 5-10 min in the liquid nitrogen, flash frozen tissue cryogenic vials are transported on dry ice to -80°C freezers for long-term storage. Biospecimen resource personnel must record storage conditions and thawing episodes. Minimizing thawing episodes eliminates variables that can compromise the quality of the specimens. Back-up equipment must be available to accommodate unforeseen emergencies that may jeopardize integrity of the samples.
Independent specimen review
A board certified pathologist reviews each slide in comparison to the clinical pathology report to confirm diagnosis, evaluate inclusion criteria, and provide further histologic characteristics. Using appropriate pathology technique, magnification, and diagnostic criteria, the pathologist will confirm diagnosis. All elements included are listed in Table 1 .
Clinical data and demographics, and ethics
Common data elements include patient demographics, risk factors, viral studies, treatment history-including local regional therapy, for example, radiofrequency ablation (RFA) and transarterial chemoembolization (TACE)-laboratory values, and the patient's recurrence history. It is essential to keep a meticulous database that correlates with a thorough inventory of specimens collected, as directed by the research questions being asked. Because this database may serve as the basis for many research questions in the future, it is prudent to record all the information potentially pertinent, and to refine the data collection as appropriate [4] .
Clinical databases are an essential component of a comprehensive and useful bioresource bank. The first concerns in establishing a data set are security and informed consent. Institutional review boards are to be assured of the safety measures put into place to protect the identity and rights of participating individuals. As genomic science continues to evolve, and as the amount of information available increases, the issues of privacy and ethics are paramount and, frankly, more convoluted [19, 20] . This is reflected in the literature as ethical, legal, and social Implications (ELSI) [21] . Obtaining patient consent is an involved process that requires investigators to be forthright about the risks associated with genomic analysis and its inherent preclusion of true anonymity [22] . Patients must be told that this is a new field of study, with unanswered possibilities, and that their rights as research participants and as patients are two separate entities. This is especially important in the liver transplant population; the point must be made clear that their transplant and care are not predicated on their participation. The responsibility also lies with the investigator to maintain limited and secure access to the scientific database. The informed consent and clinical information must be protected rigorously, and the security measures must be supported by each institution's institutional review board.
Practicalities and pitfalls
Appropriate design is essential to an effective tissuebanking program. As we hone and perfect our processes and methodology, we have overcome a few obstacles that deserve attention. Two concerns to which appropriate attention must be paid are volume and accrual. Hepatic resection and liver transplantation are relatively infrequent events carried out on an erratic schedule for varying reasons, and they require dedication of the entire staff and conscientious tissue collection. To accumulate an acceptable number of samples, collaboration may be key to the success of a nascent tissue bank. Enlisting the collection efforts of neighboring institutions and regional liver transplant surgeons has enabled Baylor to increase the size of the HCC tissue bank.
In considering the problems associated with accrual, a point of importance is the true ischemia time of the specimen. There is evidence to suggest that true ischemia time, i.e., the time from tissue excision to the time of flash freezing, is inversely correlated with retrievable protein [17] . Definition of true ischemia time is difficult to standardize, however, and some investigators would argue that it begins with cessation of blood flow. Typically, the goal is to retrieve tissue within the first 30 min after cessation of blood flow. The practicalities of tissue collection and stabilization in under 30 min is logistically difficult in real time. However, an SOP helps to regiment the practice, which is also facilitated by employing a full-time tissue collection staff whose members are experienced in the expeditious processing of tissue. In addition, documentation of tissue collection times initiates a footprinting mechanism that can be investigated should any problems arise in the quality of specimens. One issue we have found in our sequencing is specific to hepatocellular carcinoma. During the pathology review, there is significant heterogeneity of tumor histology, with significant amounts of necrosis and stroma, consistent with the pathology of the disease. Even with significant experience, it is difficult for those collecting tissues to select only viable tumor with appropriate cellularity, especially in light of the rigorous acceptance criteria for sequencing. Additionally, the top slide, used as a representation of the tissue analyzed may not replicate exactly the genetic sequence of the actual tissue analyzed. Technologies are evolving that should help expedite pathological assessment of tissue cellularity, enabling faster and more accurate processing. We are experimenting with these newer technologies, but until their usefulness has been established, we submit only our most histologically reliable samples for sequencing. It is important to note that we bank all of our liver tissue, and while not all tissue samples will meet TCGA criteria, they will remain banked. We keep our tumor bank database well annotated as technology lurches forward with more precise developments requiring less tissue, our bank can still be culled for viable analytes that may earlier have been passed over.
Another point of discussion involves the inclusion criteria used to assess for specimens that meet TCGA standards. As we search for disease biology, it is important to identify and, if possible, separate confounding genetic signatures that arise from biological stresses [23] . Cancerous tissue is ideal for this purpose when it has not been treated, specifically with chemotherapeutics. Some investigators note that the chemotherapeutics often used in TACE procedures (e.g., cisplatin, doxorubicin, and mitomycin) are DNA-altering agents that can change the genomic sequences of the original tumor. The great majority of HCCs selected for surgical intervention have a history of treatment in a standard of care as a bridge to liver transplantation [2] . Such treatments dramatically limit the number of specimens that meet TCGA standards. Discussion continues on the advantages and disadvantages of excluding such a large number of high-quality samples.
While basic science research questions become more difficult to answer with reliability, answers to clinical questions can still offer a great deal of information, especially with regard to therapeutic mechanisms and risks of recurrence.
Informatics is an essential component of a comprehensive cancer center intent on DNA sequencing and validation studies [24] . While it is not integral to the bioresource banking process itself, it is responsible for the quality and organization of the output, which can be sizable and unwieldy if not contained by a strong informatics resource. Validation studies are essential to assure quality and reproducibility of tissue sequences, and they serve as the foundation on which to build research questions and results [25] . Our facilities now use a combination of 454 and SoliD technologies to validate our sequences, while continuously searching for more state-of-the-art technologies [9] .
Conclusions
Technology has accelerated to a point where we can understand cancer as never before. With new advances, we have the potential to elucidate the genomic fundamentals of cancer formation, and thus treat it, by stratifying risk, treatments, and/or surgical options. This point cannot be understated. To build useful resources that will guide diagnosis and treatment of HCC and other cancers, it is imperative to use the cancerous tissue to which surgeons have direct access. Creating a bioresource bank, while a daunting task, is a necessary resource that will allow investigators to sequence the DNA and identify susceptible genes and possible molecular therapeutic targets.
Although we have encountered obstacles as we establish our biobank, they are not insurmountable. Volume, ischemia time, tissue histology, inclusion criteria and informatics are all issues to which one must attend. However, with a dedicated, multidisciplinary team and appropriate resources and support, the formation of a sustainable, productive system is absolutely feasible and warranted. Most important in its creation, an excellent bioresource bank can be used to record and apply the staggering advances and immense progress made each day in personalized genomic medicine, taking us one step closer to better care for our patients.
